Institution Directory

Clinical trials at Children's Hospital of Philadelphia

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

600

Shown on this page

Current sort

Live official records

Conditions: Smoking, Smoking Cessation, Second Hand Tobacco Smoke
Interventions: Refer2Quit; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years and older
Enrollment: 3,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Educational Intervention, FitBit, Goal Setting, Health Promotion and Education, Media Intervention, Telephone-Based Intervention; Other · Device · Behavioral
Lead sponsor: Children's Oncology Group; Network
Eligibility: 15 Years to 20 Years
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 114
States / cities: Mobile, Alabama • Mesa, Arizona • Downey, California + 92 more

Conditions: Neutropenia
Interventions: Mavorixafor, Placebo; Drug
Lead sponsor: X4 Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 22
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more

Conditions: Ulcerative Colitis
Interventions: tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 19
States / cities: Los Angeles, California • San Francisco, California • Farmington, Connecticut + 10 more

Conditions: Cystic Fibrosis
Interventions: Immediate Oral Antibiotics, Tailored Treatment: Oral Antibiotics only if Additional Treatment needed; Other
Lead sponsor: University of Washington, the Collaborative Health Studies Coordinating Center; Other
Eligibility: 3 Years to 18 Years
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 31
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more

Conditions: Juvenile Idiopathic Arthritis (JIA)
Interventions: Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 8
States / cities: Chicago, Illinois • Louisville, Kentucky • Boston, Massachusetts + 5 more

Conditions: Bile Acid Synthesis Disorders
Interventions: Cholbam; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2039
U.S. locations: 24
States / cities: Birmingham, Alabama • Palo Alto, California • San Francisco, California + 18 more

Conditions: Myasthenia Gravis
Interventions: Nipocalimab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 11
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more

Conditions: Mechanical Ventilation, Pediatric Acute Respiratory Failure, Analgesics, Opioid, Sedation and Analgesia
Interventions: Acetaminophen, Ketorolac, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 2 Months to 17 Years
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 16
States / cities: Little Rock, Arkansas • Washington D.C., District of Columbia • Ann Arbor, Michigan + 13 more

Conditions: Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Metastatic Embryonal Rhabdomyosarcoma, Metastatic Rhabdomyosarcoma, Solid Alveolar Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Vincristine Sulfate, Vinorelbine Tartrate, X-Ray Imaging; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 50 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 228
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 160 more

Conditions: Autosomal Dominant Hypocalcemia (ADH)
Interventions: Encaleret, Standard of Care; Drug · Dietary Supplement
Lead sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company; Industry
Eligibility: 16 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 11
States / cities: Oakland, California • Aurora, Colorado • Indianapolis, Indiana + 8 more

Conditions: Neurofibromatosis Type 1
Interventions: HLX-1502; Drug
Lead sponsor: Healx Limited; Industry
Eligibility: 12 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more

About this Children's Hospital of Philadelphia institution page

What this page lists: ClinicalTrials.gov records that list Children's Hospital of Philadelphia in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Children's Hospital of Philadelphia

Filter and sort this campus

Live official records

Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network

Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

The REPLACE Registry for Cholbam® (Cholic Acid)

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Optimizing Pain Treatment in Children On Mechanical Ventilation

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

About this Children's Hospital of Philadelphia institution page